|
Valeant Appoints William D. Humphries As EVP, Dermatology
|
12/12/16
|
Valeant Appoints William D. Humphries As EVP, Dermatology
|
PDF
|
|
Valeant Pharmaceuticals Announces Phase 3 Results For Psoriasis Treatment IDP-118
|
12/08/16
|
Valeant Pharmaceuticals Announces Phase 3 Results For Psoriasis Treatment IDP-118
|
PDF
|
|
Valeant Announces The Initiation Of A Primary Care Sales Force For Xifaxan® And Relistor®
|
11/29/16
|
Valeant Announces The Initiation Of A Primary Care Sales Force For Xifaxan® And Relistor®
|
PDF
|
|
Valeant Comments On Issued Philidor Criminal Charges
|
11/17/16
|
Valeant Comments On Issued Philidor Criminal Charges
|
PDF
|
|
Valeant Pharmaceuticals To Participate In Healthcare Conferences
|
11/10/16
|
Valeant Pharmaceuticals To Participate In Healthcare Conferences
|
PDF
|
|
Valeant Reports Third Quarter 2016 Financial Results
|
11/08/16
|
Valeant Reports Third Quarter 2016 Financial Results
|
pdf
|
|
Valeant Pharmaceuticals Comments On Press Report Regarding Its Gastroenterology Business Unit
|
11/01/16
|
Valeant Pharmaceuticals Comments On Press Report Regarding Its Gastroenterology Business Unit
|
PDF
|
|
Valeant Pharmaceuticals Comments On Press Report
|
10/31/16
|
Valeant Pharmaceuticals Comments On Press Report
|
PDF
|
|
Valeant Announces Third Quarter Financial Results Date And Conference Call Details
|
10/17/16
|
Valeant Announces Third Quarter Financial Results Date And Conference Call Details
|
PDF
|
|
Valeant Patient Access And Pricing Committee Comments On Recent Pricing Action Decisions
|
10/14/16
|
Valeant Patient Access And Pricing Committee Comments On Recent Pricing Action Decisions
|
PDF
|
|
Valeant Appoints Louis W. Yu, Ph.D. As Chief Quality Officer
|
10/06/16
|
Valeant Appoints Louis W. Yu, Ph.D. As Chief Quality Officer
|
PDF
|
|
Valeant Comments On Discount And Rebate Program For Nitropress And Isuprel
|
09/16/16
|
Valeant Comments On Discount And Rebate Program For Nitropress And Isuprel
|
PDF
|
|
Valeant And Progenics Announce The U.S. Commercial Launch Of FDA-Approved Relistor® Tablets
|
09/06/16
|
Valeant And Progenics Announce The U.S. Commercial Launch Of FDA-Approved Relistor® Tablets
|
PDF
|
|
Valeant Pharmaceuticals To Participate In September Healthcare Conferences
|
08/30/16
|
Valeant Pharmaceuticals To Participate In September Healthcare Conferences
|
PDF
|
|
Valeant Pharmaceuticals Appoints Paul S. Herendeen As Executive Vice President, Finance And Chief Financial Officer
|
08/22/16
|
Valeant Pharmaceuticals Appoints Paul S. Herendeen As Executive Vice President, Finance And Chief Financial Officer
|
PDF
|
|
Valeant Pharmaceuticals Receives Lender Consent For Credit Facility Amendment
|
08/18/16
|
Valeant Pharmaceuticals Receives Lender Consent For Credit Facility Amendment
|
PDF
|
|
Valeant Pharmaceuticals Comments On SDNY Investigation
|
08/10/16
|
Valeant Pharmaceuticals Comments On SDNY Investigation
|
PDF
|
|
Valeant Pharmaceuticals Reports Second Quarter 2016 Financial Results
|
08/09/16
|
Valeant Pharmaceuticals Reports Second Quarter 2016 Financial Results
|
PDF
|
|
Valeant Pharmaceuticals Announces Significant Support For Education And Research Regarding Wilson Disease
|
08/08/16
|
Valeant Pharmaceuticals Announces Significant Support For Education And Research Regarding Wilson Disease
|
PDF
|
|
Valeant Pharmaceuticals Announces Relaunch Of Generic Ofloxacin Otic Solution
|
08/08/16
|
Valeant Pharmaceuticals Announces Relaunch Of Generic Ofloxacin Otic Solution
|
PDF
|
|
Valeant Pharmaceuticals Announces Licensing Agreement With Norgine B.V. For NER1006 In U.S. And Canada
|
08/08/16
|
Valeant Pharmaceuticals Announces Licensing Agreement With Norgine B.V. For NER1006 In U.S. And Canada
|
PDF
|
|
Valeant Pharmaceuticals Announces Changes To Executive Management Team
|
08/08/16
|
Valeant Pharmaceuticals Announces Changes To Executive Management Team
|
PDF
|
|
Valeant Pharmaceuticals Announces The Addition Of Sarah B. Kavanagh To Its Board Of Directors
|
07/28/16
|
Valeant Pharmaceuticals Announces The Addition Of Sarah B. Kavanagh To Its Board Of Directors
|
PDF
|
|
Valeant Pharmaceuticals Receives Complete Response Letter From The FDA
|
07/22/16
|
Valeant Pharmaceuticals Receives Complete Response Letter From The FDA
|
PDF
|
|
Valeant and Progenics Announce FDA Approves RELISTOR® Tablets for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-cancer Pain
|
07/19/16
|
Valeant and Progenics Announce FDA Approves RELISTOR® Tablets for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-cancer Pain
|
PDF
|
|
FDA Advisory Committee Recommends Approval Of Brodalumab For Treatment Of Moderate-To-Severe Plaque Psoriasis
|
07/19/16
|
FDA Advisory Committee Recommends Approval Of Brodalumab For Treatment Of Moderate-To-Severe Plaque Psoriasis
|
PDF
|
|
Valeant Pharmaceuticals Announces Second Quarter Results Conference Call Date And Details
|
07/15/16
|
Valeant Pharmaceuticals Announces Second Quarter Results Conference Call Date And Details
|
PDF
|
|
Valeant Pharmaceuticals Comments On Recent Stock Transactions
|
07/14/16
|
Valeant Pharmaceuticals Comments On Recent Stock Transactions
|
PDF
|
|
Bausch + Lomb and Nicox Announce the Publication of Latanoprostene Bunod Ophthalmic Solution 0.024% Phase 3 Study Results in American Journal of Ophthalmology
|
07/06/16
|
Bausch + Lomb and Nicox Announce the Publication of Latanoprostene Bunod Ophthalmic Solution 0.024% Phase 3 Study Results in American Journal of Ophthalmology
|
PDF
|
|
Valeant Pharmaceuticals Announces New Licensing Arrangement For Brodalumab In Europe
|
07/01/16
|
Valeant Pharmaceuticals Announces New Licensing Arrangement For Brodalumab In Europe
|
PDF
|
|
Canadian Shopper Study Names Bausch + Lomb Most Trusted Brand For Contact Lens Care
|
06/27/16
|
Canadian Shopper Study Names Bausch + Lomb Most Trusted Brand For Contact Lens Care
|
PDF
|
|
Valeant Pharmaceuticals Announces Significant Investments In Canadian Operations
|
06/17/16
|
Valeant Pharmaceuticals Announces Significant Investments In Canadian Operations
|
PDF
|
|
Valeant Pharmaceuticals Announces Launch Of New PreserVision® AREDS 2 Formula + Multivitamin
|
06/16/16
|
Valeant Pharmaceuticals Announces Launch Of New PreserVision® AREDS 2 Formula + Multivitamin
|
PDF
|
|
Valeant Pharmaceuticals Appoints Thomas W. Ross, Sr. Lead Independent Director
|
06/15/16
|
Valeant Pharmaceuticals Appoints Thomas W. Ross, Sr. Lead Independent Director
|
PDF
|
|
Valeant To Participate In FDA Advisory Committee Meeting On July 19
|
06/09/16
|
Valeant To Participate In FDA Advisory Committee Meeting On July 19
|
PDF
|
|
Valeant Pharmaceuticals To Webcast 2016 Annual Meeting Of Shareholders
|
06/07/16
|
Valeant Pharmaceuticals To Webcast 2016 Annual Meeting Of Shareholders
|
PDF
|
|
Valeant Pharmaceuticals Reports First Quarter 2016 Financial Results
|
06/07/16
|
Valeant Pharmaceuticals Reports First Quarter 2016 Financial Results
|
PDF
|
|
Valeant Pharmaceuticals Receives Additional Notice Of Default Under Indentures Due To Delayed Form 10-Q Filing
|
06/03/16
|
Valeant Pharmaceuticals Receives Additional Notice Of Default Under Indentures Due To Delayed Form 10-Q Filing
|
PDF
|
|
Valeant Pharmaceuticals To Present Six Abstracts At 2016 ASCO Annual Meeting
|
06/01/16
|
Valeant Pharmaceuticals To Present Six Abstracts At 2016 ASCO Annual Meeting
|
PDF
|
|
Valeant Pharmaceuticals To Hold Conference Call On June 7, 2016
|
05/31/16
|
Valeant Pharmaceuticals To Hold Conference Call On June 7, 2016
|
PDF
|
|
Valeant Pharmaceuticals Names Sam Eldessouky Senior Vice President And Corporate Controller
|
05/26/16
|
Valeant Pharmaceuticals Names Sam Eldessouky Senior Vice President And Corporate Controller
|
PDF
|
|
Bausch + Lomb Wins Walmart "Supplier of the Year" Award
|
05/23/16
|
Bausch + Lomb Wins Walmart "Supplier of the Year" Award
|
PDF
|
|
Valeant Pharmaceuticals Receives Notice Of Default From Bondholders
|
05/19/16
|
Valeant Pharmaceuticals Receives Notice Of Default From Bondholders
|
PDF
|
|
Valeant Pharmaceuticals To Participate At The UBS Global Healthcare Conference
|
05/18/16
|
Valeant Pharmaceuticals To Participate At The UBS Global Healthcare Conference
|
PDF
|
|
Valeant Pharmaceuticals Provides Update Regarding Regulatory Matters
|
05/16/16
|
Valeant Pharmaceuticals Provides Update Regarding Regulatory Matters
|
PDF
|
|
Valeant Pharmaceuticals Announces Expanded Discounts For Nitropress And Isuprel
|
05/16/16
|
Valeant Pharmaceuticals Announces Expanded Discounts For Nitropress And Isuprel
|
PDF
|
|
Valeant Pharmaceuticals Announces Expected Timing Of Form 10-Q Filing And Reiterates 2016 First Quarter Guidance
|
05/09/16
|
Valeant Pharmaceuticals Announces Expected Timing Of Form 10-Q Filing And Reiterates 2016 First Quarter Guidance
|
PDF
|
|
Valeant Pharmaceuticals Announces Patient Access And Pricing Committee To Oversee Pricing Of Drugs
|
05/05/16
|
Valeant Pharmaceuticals Announces Patient Access And Pricing Committee To Oversee Pricing Of Drugs
|
PDF
|
|
Valeant Pharmaceuticals Announces Collaboration Between Bausch + Lomb And IBM
|
05/05/16
|
Valeant Pharmaceuticals Announces Collaboration Between Bausch + Lomb And IBM
|
PDF
|
|
Joseph C. Papa Assumes Role Of Chairman And Chief Executive Officer Of Valeant Pharmaceuticals
|
05/03/16
|
Joseph C. Papa Assumes Role Of Chairman And Chief Executive Officer Of Valeant Pharmaceuticals
|
PDF
|
|
Valeant Announces Nominees For Election To Board Of Directors
|
04/29/16
|
Valeant Announces Nominees For Election To Board Of Directors
|
PDF
|
|
Valeant Pharmaceuticals Files Annual Report On Form 10-K For Year Ended December 31, 2015
|
04/29/16
|
Valeant Pharmaceuticals Files Annual Report On Form 10-K For Year Ended December 31, 2015
|
PDF
|
|
Valeant Names Joseph C. Papa To Be Chairman And Chief Executive Officer Of Valeant Pharmaceuticals
|
04/25/16
|
Valeant Names Joseph C. Papa To Be Chairman And Chief Executive Officer Of Valeant Pharmaceuticals
|
PDF
|
|
Valeant Pharmaceuticals Receives Additional Notices Of Default Under Indentures Due To Delayed 10-K Filing
|
04/22/16
|
Valeant Pharmaceuticals Receives Additional Notices Of Default Under Indentures Due To Delayed 10-K Filing
|
PDF
|
|
Valeant Pharmaceuticals Provides Update Regarding Regulatory Matters
|
04/13/16
|
Valeant Pharmaceuticals Provides Update Regarding Regulatory Matters
|
PDF
|
|
Valeant Pharmaceuticals Receives Notice Of Default From Bondholders Due To Delayed 10-K Filing
|
04/12/16
|
Valeant Pharmaceuticals Receives Notice Of Default From Bondholders Due To Delayed 10-K Filing
|
PDF
|
|
Valeant Board Of Directors Issues Statement On J. Michael Pearson's Cooperation With Senate Committee on Aging
|
04/11/16
|
Valeant Board Of Directors Issues Statement On J. Michael Pearson's Cooperation With Senate Committee on Aging
|
PDF
|
|
Valeant Pharmaceuticals Receives Lender Consent For Credit Facility Amendment
|
04/07/16
|
Valeant Pharmaceuticals Receives Lender Consent For Credit Facility Amendment
|
PDF
|
|
Valeant Ad Hoc Committee Announces Completion Of Its Review Of Philidor And Related Accounting Matters
|
04/05/16
|
Valeant Ad Hoc Committee Announces Completion Of Its Review Of Philidor And Related Accounting Matters
|
PDF
|
|
Valeant and Progenics Announce PDUFA Date Extension for Oral RELISTOR
|
04/04/16
|
Valeant and Progenics Announce PDUFA Date Extension for Oral RELISTOR
|
PDF
|
|
Valeant Pharmaceuticals Launches Credit Facility Amendment
|
03/30/16
|
Valeant Pharmaceuticals Launches Credit Facility Amendment
|
PDF
|
|
Valeant Announces CEO Succession Plan And Changes To Board Of Directors; Provides Accounting And Financial Reporting Update
|
03/21/16
|
Valeant Announces CEO Succession Plan And Changes To Board Of Directors; Provides Accounting And Financial Reporting Update
|
PDF
|
|
/C O R R E C T I O N -- Valeant Pharmaceuticals International, Inc./
|
03/15/16
|
/C O R R E C T I O N -- Valeant Pharmaceuticals International, Inc./
|
PDF
|
|
Valeant And R&O Pharmacy End Litigation
|
03/09/16
|
Valeant And R&O Pharmacy End Litigation
|
PDF
|
|
Valeant Pharmaceuticals Announces The Addition Of Three New Independent Directors To Its Board
|
03/09/16
|
Valeant Pharmaceuticals Announces The Addition Of Three New Independent Directors To Its Board
|
PDF
|
|
Valeant Pharmaceuticals To Hold Conference Call On March 15, 2016
|
03/07/16
|
Valeant Pharmaceuticals To Hold Conference Call On March 15, 2016
|
PDF
|
|
Valeant Pharmaceuticals To Hold Conference Call On March 15, 2016
|
03/07/16
|
Valeant Pharmaceuticals To Hold Conference Call On March 15, 2016
|
PDF
|
|
Valeant Pharmaceuticals Comments On Management Change
|
03/03/16
|
Valeant Pharmaceuticals Comments On Management Change
|
PDF
|
|
Valeant Pharmaceuticals Announces Management Change
|
03/02/16
|
Valeant Pharmaceuticals Announces Management Change
|
PDF
|
|
Valeant Pharmaceuticals Announces Management And Business Update
|
02/28/16
|
Valeant Pharmaceuticals Announces Management And Business Update
|
PDF
|
|
Valeant Ad Hoc Committee has Made Substantial Progress in Its Review of Philidor and Related Accounting Matters
|
02/22/16
|
Valeant Ad Hoc Committee has Made Substantial Progress in Its Review of Philidor and Related Accounting Matters
|
PDF
|
|
Valeant Announces FDA Acceptance of BLA Submission for Brodalumab in Moderate-to-Severe Plaque Psoriasis
|
01/25/16
|
Valeant Announces FDA Acceptance of BLA Submission for Brodalumab in Moderate-to-Severe Plaque Psoriasis
|
PDF
|
|
Valeant Provides Update On J. Michael Pearson
|
01/25/16
|
Valeant Provides Update On J. Michael Pearson
|
PDF
|
|
Valeant Names Howard B. Schiller Interim CEO
|
01/06/16
|
Valeant Names Howard B. Schiller Interim CEO
|
PDF
|
|
Valeant Pharmaceuticals To Present At The 34th Annual J.P. Morgan Healthcare Conference
|
01/04/16
|
Valeant Pharmaceuticals To Present At The 34th Annual J.P. Morgan Healthcare Conference
|
PDF
|
